Center for Targeted Therapeutics

靶向治疗中心

• 批准号: 10403528
• 负责人: Hippokratis Kiaris
• 金额: $ 223.5万
• 依托单位: UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-07-10 至 2024-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10403528
• 关键词: Address; Alzheimer' s Disease; Applications Grants; Area; Automobile Driving; Award; Biology; Career Mobility; Cellular biology; Centers of Research Excellence; Chemicals; Collaborations; Complement; Core Facility; Databases; Development; Developmental Biology; Disease; Drug Compounding; Drug Design; Economic Development; Education; Educational workshop; Environment; Equipment; Faculty; Financial Support; Flow Cytometry; Fostering; Friends; Funding; Future; Goals; Grant; Interdisciplinary Study; Laboratories; Malignant Neoplasms; Medical; Mentors; Microscopy; Mission; Molecular Target; Paper; Pharmaceutical Preparations; Pharmacotherapy; Phase; Pilot Projects; Play; Process; Public Health; Publishing; Reporting; Research; Research Infrastructure; Research Personnel; Research Project Grants; Research Support; Resource Sharing; Resources; Scientist; Senior Scientist; Services; Small Business Innovation Research Grant; Small Business Technology Transfer Research; South Carolina; Structure; Talents; Technology; Therapeutic; Therapeutic Human Experimentation; Training; United States National Institutes of Health; Universities; Vision; Work; cancer genomics; career development; cellular targeting; college; common treatment; drug discovery; drug synthesis; faculty mentor; functional genomics; high risk; infrastructure development; instrumentation; interest; meetings; member; multidisciplinary; new therapeutic target; next generation; operation; programs; prototype; recruit; research and development; senior faculty; success; targeted treatment; tenure track

ABSTRACT The principal Phase II goal of the COBRE Center for Targeted Therapeutics (CTT) is to conduct vital research oriented at identifying novel drug targets and discovering new targeted drugs, while enhancing the career development and research competitiveness of Center investigators. Targeted therapeutics is a broad term for research that seeks to develop new and more effective classes of drugs against various diseases, by selectively aiming these drugs at molecular and cellular targets that play a key role in the disease. The area of Targeted Therapeutics has been chosen because of its societal impact, the emergence of common technologies driving therapeutics research in different disease areas, and the presence of a critical core of senior faculty with broad acumen and trans-disciplinary vision in Targeted Therapeutics at USC. During Phase I, junior investigators leading CTT research projects (target PIs) were awarded five R01s and several smaller grants, and pilot project recipients received two R01s and several other grants, for a total of close to $14 million. Four target PIs received promotion and tenure and almost 50 published papers acknowledged COBRE support. Three resource cores established by the CTT provided services to 64 different laboratories and organized training workshops and a new graduate course. To build upon the success of Phase I, we will pursue the following Specific Aims. Aim 1. Support high-impact research projects and assist junior scientists in Targeted Therapeutics in their professional development and competitiveness for NIH grants, in a collaborative and nurturing environment. Target junior faculty members include four highly promising scientists, each of whom will be mentored by two senior scientists with different areas of expertise relevant to their research. Aim 2. Establish sustainable research infrastructure through the further development of strategic Cores for Targeted Therapeutics research. The Center supports research cores in Functional Genomics, Drug Design and Synthesis, and Microscopy and Flow Cytometry. These cores will provide both specialized services and intellectual scientific support. Aim 3. Assure long-term development of the CTT by broadening collaborative networking, fostering continuous recruitment, supporting new faculty in Targeted Therapeutics, and supporting pilot research projects, with an emphasis on drug discovery and preparation for multi-investigator and SBIR/STTR grant applications. CTT will conduct regular meetings and seminars and promote external collaborations. CTT will participate in the recruitment of five new junior faculty members to USC and will continue working with the “graduated” target faculty, assuring that they continue to make important discoveries and win grants. Continued success of the CTT will make an impact on the public health, scientific education and economic development of the State.

摘要 COBRE靶向治疗中心（CTT）的主要II期目标是进行重要的研究 致力于发现新的药物靶点，发现新的靶向药物， 中心研究人员的发展和研究竞争力。靶向治疗是一个广义的术语， 通过选择性地开发新的和更有效的药物来治疗各种疾病的研究。 将这些药物瞄准在疾病中起关键作用的分子和细胞靶点。目标区域 选择治疗学是因为它的社会影响，通用技术的出现， 在不同的疾病领域的治疗研究，以及具有广泛的高级教师的关键核心的存在 敏锐和跨学科的视野在南加州大学靶向治疗。在第一阶段，初级研究人员 领先的CTT研究项目（目标PI）获得了五个R 01和几个较小的赠款，以及试点项目 接受者获得了两个R 01和其他几个赠款，总额接近1 400万美元。收到4个目标PI 近50篇已发表的论文承认了COBRE的支持。三大资源核心 由CTT建立的实验室为64个不同的实验室提供服务，并组织培训讲习班和 新的研究生课程在第一阶段取得成功的基础上，我们将继续努力实现以下具体目标。 目标1.支持高影响力的研究项目，并协助初级科学家在靶向治疗， 专业发展和竞争力的NIH赠款，在合作和培育环境。 目标初级教员包括四名非常有前途的科学家， 具有与其研究相关的不同专业领域的资深科学家。 目标二。通过进一步发展战略核心，建立可持续的研究基础设施， 有针对性的治疗研究。该中心支持功能基因组学、药物设计和 合成、显微镜检查和流式细胞术。这些核心将提供专门的服务， 智力科学支持。 目标3.通过扩大合作网络，促进持续的 招聘，支持靶向治疗的新教师，并支持试点研究项目， 重点是药物发现和准备多研究者和SBIR/STTR补助金申请。CTT将 定期举行会议和研讨会，促进外部合作。CTT将参加 南加州大学招聘了五名新的初级教师，并将继续以“毕业”为目标 教师，确保他们继续作出重要的发现，并赢得赠款。CTT的持续成功 将对国家的公共卫生、科学教育和经济发展产生影响。